MFS Medifocus Inc

Medifocus Inc. (Medifocus) (TSX VENTURE:MFS)(OTCQX:MDFXF) announces that,
further to its August 8, 2013 press release, it has extended its previously
announced offering of units. Subject to regulatory approval, Medifocus is
offering up to $6,000,000 worth of units (the Units) at a price of $10,000 per
Unit by way of a non-brokered private placement (the Offering). Each Unit
consists of (i) redeemable promissory notes, bearing 8% annual interest payable
on a quarterly basis (Notes), which are convertible into common shares (Common
Shares) at a conversion price of $0.25 per Common Share, and which are payable
36 months after the closing of the Offering; and (ii) Common Share purchase
warrants to purchase up to one-half the number of Common Shares resulting from
such conversion (Series C Warrants). Each whole Series C Warrant will entitle
the holder to purchase one additional Common Share at a price of $0.30 per
Common Share for a period of 36 months following the completion of the Offering.


If, at any time after the date that is 12 months following the closing of the
Offering, the daily volume weighted average trading price of the Common Shares
on the TSX Venture Exchange or the OTCQX in the United States exceeds $0.50 (or
its equivalent in U.S. dollars) for at least 20 consecutive trading days,
Medifocus may at its sole discretion, within 30 days of such occurrence, provide
a redemption notice to the holders of Notes and, if it does so, Medifocus will
redeem Notes by paying the holders thereof the principal amount of such Notes
plus any accrued but unpaid interest on the 30th day after the redemption notice
is given.


If, at any time after the date that is 12 months following the closing of the
Offering, the daily volume weighted average trading price of the Common Shares
on the TSX Venture Exchange or the OTCQX in the United States exceeds $0.60 (or
its equivalent in U.S. dollars) for at least 20 consecutive trading days,
Medifocus may, within 30 days of such occurrence, provide an expiry acceleration
notice to the holders of Series C Warrants and, if it does so, the Series C
Warrants will, unless exercised, expire on the 30th day after the acceleration
notice is given.


Medifocus anticipates that the Offering will be completed on or around November
15, 2013.


Medifocus may pay finder's fees equal to 9% of the gross proceeds raised and
issue non-transferable finder's warrants to purchase up to 9% of the number of
Common Shares underlying the Units sold in the Offering. Each finder's warrant
will entitle the holder to purchase one additional Common Share at a price of
$0.30 per Common Share for a period of 24 months following the completion of the
Offering.


Assuming that the aggregate gross proceed of the Offering are $6,000,000, the
net proceeds of the Offering will be used: (i) to commercialize the Prolieve(R)
line of business (55%); (ii) for working capital (30%); and (iii) to continue
Medifocus' pivotal phase III clinical trials using Medifocus' Microfocus APA
1000 System for the treatment of breast cancer including all related
professional expenses (15%).


About Medifocus

Medifocus owns two fully developed technology platforms with comprehensive
United States and international patent protection: (i) The Endo-thermotherapy
Platform-a catheter-basis focused heat technology platform that utilizes natural
body openings to deliver precise microwave thermotherapy to the diseased sites.
The United States Food and Drugs Administration (FDA) approved Prolieve
Thermodilatation System for the treatment of Benign Prostatic Hyperplasia (BPH)
was developed based on the Endo-thermotherapy and is currently generating
revenue; and (ii) the Adaptive Phased Array (APA) Microwave Focusing Platform,
invented by the Massachusetts Institute of Technology, licensed to Medifocus
directs precisely focused microwave energy at tumor center to induce shrinkage
or eradication of tumors without undue harm to surrounding tissue. Medifocus'
APA 1000 Breast Cancer Treatment System, developed from the APA technology
platform, has received approval from the FDA and Health Canada to conduct the
pivotal Phase III clinical trials. Medifocus believes that these two technology
platforms can provide the design basis for the development of multiple cancer
treatment systems for surface, subsurface and deep seated localized and regional
cancers. Please visit www.medifocusinc.com, www.prolieve.com and
http://www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627 for
more details. 


Forward-Looking Statements and Information

This news release contains "forward-looking statements" and "forward-looking
information", which may not be based on historical facts. Forward-looking
statements and forward-looking information, include, but are not limited to,
information and statements with respect the structure and the proceeds of the
Offering and the expected use of the proceeds. Forward-looking statements are
frequently characterized by words such as "plan", "expect", "project", "intend",
"believe", "anticipate", "estimate" and other similar words, or statements that
certain events or conditions "may" or "will" occur. Forward-looking statements
are based on the opinions and estimates of management at the date the statements
are made. Such forward-looking statements and forward-looking information
involve known and unknown risks, uncertainties and other factors that may cause
the actual results events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements or forward-looking information. These factors should
be considered carefully and readers are cautioned not to place undue reliance on
such forward-looking statements and forward-looking information. Except as
required by applicable securities laws, Medifocus disclaims any obligation to
update any such factors or to publicly announce the results of any revisions to
any of the forward-looking statements or forward-looking information contained
herein to reflect future results, events or developments.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Medifocus Inc.
John Mon
COO
410-290-5734
JohnMon@medifocusinc.com


Investor Relations Contact
Robert Giordano
Consulting for Strategic Growht 1
917-327-3938
rgiordanonyc@gmail.com

Grafico Azioni Medifocus (TSXV:MFS)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Medifocus (TSXV:MFS)
Storico
Da Giu 2023 a Giu 2024